This company has been acquired
LogicBio Therapeutics Management
Management Kriterienprüfungen 1/4
Wichtige Informationen
Fred Chereau
Geschäftsführender
US$2.2m
Gesamtvergütung
Prozentsatz des Geschäftsführergehalts | 24.3% |
Amtszeit als Geschäftsführer | 6.6yrs |
Eigentum des Geschäftsführers | 0.8% |
Durchschnittliche Amtszeit des Managements | 1.8yrs |
Durchschnittliche Amtszeit der Vorstandsmitglieder | 3.4yrs |
Jüngste Management Updates
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Analyse der Geschäftsführervergütung
Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
---|---|---|---|
Sep 30 2022 | n/a | n/a | -US$27m |
Jun 30 2022 | n/a | n/a | -US$31m |
Mar 31 2022 | n/a | n/a | -US$36m |
Dec 31 2021 | US$2m | US$543k | -US$40m |
Sep 30 2021 | n/a | n/a | -US$38m |
Jun 30 2021 | n/a | n/a | -US$36m |
Mar 31 2021 | n/a | n/a | -US$33m |
Dec 31 2020 | US$2m | US$479k | -US$33m |
Sep 30 2020 | n/a | n/a | -US$37m |
Jun 30 2020 | n/a | n/a | -US$40m |
Mar 31 2020 | n/a | n/a | -US$42m |
Dec 31 2019 | US$633k | US$510k | -US$40m |
Sep 30 2019 | n/a | n/a | -US$32m |
Jun 30 2019 | n/a | n/a | -US$29m |
Mar 31 2019 | n/a | n/a | -US$23m |
Dec 31 2018 | US$2m | US$411k | -US$18m |
Sep 30 2018 | n/a | n/a | -US$18m |
Jun 30 2018 | n/a | n/a | -US$11m |
Mar 31 2018 | n/a | n/a | -US$9m |
Dec 31 2017 | US$779k | US$385k | -US$8m |
Vergütung im Vergleich zum Markt: Fred's total compensation ($USD2.23M) is above average for companies of similar size in the US market ($USD750.11K).
Entschädigung vs. Einkommen: Fred's compensation has increased whilst the company is unprofitable.
Geschäftsführer
Fred Chereau (55 yo)
6.6yrs
Amtszeit
US$2,228,208
Vergütung
Mr. Frederic Chereau, M.B.A., also known as Fred, is the Chairman of the Board of Coave Therapeutics since October 2022 and has been its Independent Non-Executive Director since October 2021. He has execut...
Führungsteam
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
President | 6.6yrs | US$2.23m | 0.77% $ 525.4k | |
Co-Founder | no data | US$156.64k | 2.38% $ 1.6m | |
Chief Medical Officer | 2.4yrs | US$1.54m | 0.010% $ 6.9k | |
Co-Founder & Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Co-Founder | 8.3yrs | keine Daten | keine Daten | |
Interim CFO | less than a year | keine Daten | keine Daten | |
Global VP & Head of Technology Development | 3.6yrs | keine Daten | keine Daten | |
Chief Scientific Officer | 2yrs | US$1.34m | keine Daten | |
General Counsel & Corporate Secretary | 1.5yrs | keine Daten | keine Daten | |
VP & Head of Human Resources | 1.2yrs | keine Daten | keine Daten | |
Senior Vice President of Strategy & Portfolio Management | 1.4yrs | keine Daten | keine Daten | |
Chief Business Officer | 1.3yrs | keine Daten | keine Daten |
1.8yrs
Durchschnittliche Betriebszugehörigkeit
55yo
Durchschnittliches Alter
Erfahrenes Management: LOGC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Vorstandsmitglieder
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
President | no data | US$2.23m | 0.77% $ 525.4k | |
Co-Founder | 6.8yrs | US$156.64k | 2.38% $ 1.6m | |
Co-Founder & Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Independent Director | 4.2yrs | US$87.39k | 0.0095% $ 6.5k | |
Independent Chairman of the Board | 4.1yrs | US$113.64k | 0.012% $ 8.1k | |
Independent Director | 2.7yrs | US$82.02k | 0.0089% $ 6.0k | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Independent Director | 6.8yrs | US$81.14k | 0.068% $ 46.2k | |
Independent Director | 1.9yrs | US$76.77k | 0% $ 0 | |
Independent Director | 1.9yrs | US$79.64k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Independent Director | less than a year | US$40.31k | keine Daten |
3.4yrs
Durchschnittliche Betriebszugehörigkeit
58yo
Durchschnittliches Alter
Erfahrener Vorstand: LOGC's board of directors are considered experienced (3.4 years average tenure).